Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome
Interventions: ONTAK; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions: Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%; Drug
Lead sponsor: Waihong Chung; Other
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Dermatitis, Atopic
Interventions: MK-6194, Placebo; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more

Conditions: Healthy
Interventions: Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Pain
Interventions: MEB-1170, Placebo; Drug
Lead sponsor: Mebias Discovery, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Peripheral Neuropathy, Chemotherapy-induced
Interventions: PROCRIT 40,000 IU QW, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 28
States / cities: Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more

Conditions: Influenza
Interventions: Placebo, Trivalent Inactivated Influenza; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Menopause, Cognitive Change, Brain Disorder, Metabolic
Interventions: PhytoSERM, Placebo; Dietary Supplement · Drug
Lead sponsor: Roberta Brinton; Other
Eligibility: 45 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Tucson, Arizona • New York, New York

Conditions: Diabetic Nephropathy
Interventions: Repository Corticotropin Injection, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 10
States / cities: Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more

Conditions: Endometriosis, Post Operative Pain
Interventions: Ketamine, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Common Cold
Interventions: Pomegranate Concentrate (POMx), Placebo; Dietary Supplement
Lead sponsor: POM Wonderful LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Huntsville, Alabama • Melbourne, Florida • Charlottesville, Virginia

Conditions: Hereditary Angioedema
Interventions: C1 Esterase Inhibitor, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 6 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Granada Hills, California • Weston, Florida • Atlanta, Georgia + 14 more

Conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions: Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 30
States / cities: Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more

Conditions: Healthy Volunteers
Interventions: E2511, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Coronary Heart Disease
Interventions: Placebo, dalcetrapib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more

Conditions: Pain Management
Interventions: Ibuprofen, APAP; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 3 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Child Development, Cannabis Use
Interventions: Placebo, Choline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Kidney Diseases, High Cholesterol
Interventions: Evolocumab, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Mineola, New York • New York, New York

Conditions: Vitamin D Deficiency
Interventions: Cholecalciferol; Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 13 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy, Immune-Mediated Neuropathy
Interventions: Panzyga IVIG, Placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Healthy Adults
Interventions: Body-Brain Trainer, Body Trainer, Brain Trainer, Expectancy Matched Control; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Dementia With Lewy Bodies
Interventions: Placebo, 192 mg powder of K0706, 384 mg powder of K0706; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 25 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Anemia, Sickle Cell
Interventions: Arginine, Placebo; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 5 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 17
States / cities: Oakland, California • San Francisco, California • Denver, Colorado + 10 more

Search by objective public record fields.

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Interaction Between ABT-335, Rosuvastatin and Warfarin

A Study to Assess the Safety of MEB-1170 in Healthy Subjects

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Th1 Response to Influenza: Aging and Vaccine Efficacy

PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study

Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

IBUPAP Study for Pain Management in Children

Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development

Evolocumab In Advanced Chronic Kidney Disease Trial

Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Characterizing the Synergistic Effects of Physical and Cognitive Training on Attention and Working Memory

K0706 for Patients Diagnosed With Dementia With Lewy Bodies

Effectiveness of Arginine as a Treatment for Sickle Cell Anemia